Drug Profile
Research programme: autoimmune disease therapy - Domantis/Tanox
Alternative Names: Autoimmune disease therapy research programme - Domantis/Tanox; Dom0800; Domain antibody therapy research programme - Domantis/TanoxLatest Information Update: 04 May 2007
Price :
$50
*
At a glance
- Originator Domantis; Tanox
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 May 2007 No development reported - Preclinical for Autoimmune disorders in United Kingdom (unspecified route)
- 07 Jan 2007 Domantis has been acquired by GlaxoSmithKline
- 04 Apr 2005 Preclinical trials in Autoimmune disorders in United Kingdom (unspecified route)